X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
aged (6) 6
female (6) 6
humans (6) 6
male (6) 6
middle aged (6) 6
adult (5) 5
gastroenterology & hepatology (5) 5
hepacivirus - genetics (5) 5
index medicus (5) 5
antiviral agents - administration & dosage (4) 4
drug therapy, combination (4) 4
gastroenterology and hepatology (4) 4
genotype (4) 4
ribavirin (4) 4
young adult (4) 4
abridged index medicus (3) 3
adolescent (3) 3
antiviral agents - adverse effects (3) 3
hepatitis c, chronic - drug therapy (3) 3
3-day monotherapy (2) 2
abt-450/r-ombitasvir (2) 2
administration, oral (2) 2
analysis (2) 2
anilides - administration & dosage (2) 2
anilides - adverse effects (2) 2
anilides - therapeutic use (2) 2
antiviral agents - therapeutic use (2) 2
biological response modifiers (2) 2
carbamates - administration & dosage (2) 2
carbamates - adverse effects (2) 2
carbamates - therapeutic use (2) 2
chronic hepatitis-c (2) 2
combination therapy (2) 2
double-blind method (2) 2
drug therapy (2) 2
genotype & phenotype (2) 2
genotype 1 infection (2) 2
hepacivirus - drug effects (2) 2
hepatitis (2) 2
hepatitis c (2) 2
hepatitis c - drug therapy (2) 2
hepatitis c virus (2) 2
hepatitis c, chronic - complications (2) 2
hepatitis c, chronic - virology (2) 2
infections (2) 2
interferon (2) 2
liver cirrhosis (2) 2
macrocyclic compounds - administration & dosage (2) 2
macrocyclic compounds - adverse effects (2) 2
macrocyclic compounds - therapeutic use (2) 2
medicine, general & internal (2) 2
proteases (2) 2
retreatment (2) 2
ribavirin - administration & dosage (2) 2
ribavirin - adverse effects (2) 2
ritonavir (2) 2
ritonavir - adverse effects (2) 2
ritonavir - therapeutic use (2) 2
sustained virological response (2) 2
time factors (2) 2
treatment outcome (2) 2
uracil - analogs & derivatives (2) 2
virus diseases (2) 2
virus-infection (2) 2
analgesics, opioid - adverse effects (1) 1
antiviral activity (1) 1
atrophy - drug therapy (1) 1
autoantibodies - blood (1) 1
biopsy (1) 1
body weight (1) 1
buprenorphine (1) 1
buprenorphine - adverse effects (1) 1
c virus-infection (1) 1
care and treatment (1) 1
carrier proteins - antagonists & inhibitors (1) 1
celiac disease (1) 1
celiac disease - diagnostic imaging (1) 1
celiac disease - drug therapy (1) 1
celiac disease - pathology (1) 1
challenge (1) 1
chronic hcv (1) 1
cirrhosis (1) 1
cohort (1) 1
combination enzyme therapy (1) 1
daclatasvir (1) 1
dasabuvir (1) 1
diabetes-mellitus (1) 1
direct-acting antivirals (1) 1
disposable autoinjector (1) 1
dna, viral - genetics (1) 1
dose-response relationship, drug (1) 1
drug combinations (1) 1
drug resistance, viral (1) 1
drug-therapy (1) 1
drug-users (1) 1
duodenum - pathology (1) 1
endoscopy, gastrointestinal (1) 1
enzyme inhibitors - administration & dosage (1) 1
enzyme inhibitors - adverse effects (1) 1
enzyme inhibitors - therapeutic use (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1604 - 1614
Journal Article
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2015, Volume 63, Issue 2, pp. 364 - 369
Journal Article
Gastroenterology, ISSN 0016-5085, 2015, Volume 149, Issue 4, pp. 971 - 980.e1
Background & Aims Interferon-free treatment options are rapidly evolving for patients with chronic hepatitis C virus (HCV) genotype 1b (GT1b) infection with... 
Gastroenterology and Hepatology | Direct-Acting Antivirals | Interferon-Free/Ribavirin-Free | HCV Genotype 1b | ABT-450/R-OMBITASVIR | CHRONIC HCV | RANDOMIZED-TRIAL | RIBAVIRIN | PEGINTERFERON ALPHA-2A | PLUS SOFOSBUVIR | DASABUVIR | TREATMENT-EXPERIENCED PATIENTS | DACLATASVIR | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | Recurrence | Anilides - therapeutic use | United States | Anilides - adverse effects | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Male | Carbamates - administration & dosage | Hepatitis C, Chronic - complications | Enzyme Inhibitors - administration & dosage | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Female | Drug Therapy, Combination | Enzyme Inhibitors - adverse effects | Hepacivirus - drug effects | Liver Cirrhosis - drug therapy | Liver Cirrhosis - diagnosis | Ritonavir - administration & dosage | Administration, Oral | Antiviral Agents - therapeutic use | Europe | Carrier Proteins - antagonists & inhibitors | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Enzyme Inhibitors - therapeutic use | Remission Induction | Macrocyclic Compounds - therapeutic use | Hepacivirus - enzymology | Liver Cirrhosis - virology | Anilides - administration & dosage | Antiviral Agents - adverse effects | Carbamates - adverse effects | Aged | Macrocyclic Compounds - administration & dosage | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Virus diseases | Medical research | Proteases | Ritonavir | Analysis | Liver | Medicine, Experimental | Biological response modifiers | Hepatitis C virus | Health aspects | Gangliosides | Liver cirrhosis
Journal Article
Journal Article
Journal Article
Patient Preference and Adherence, ISSN 1177-889X, 11/2011, Volume 2011, Issue default, pp. 587 - 599
Peter Varunok1, Eric Lawitz2, Kimberly L Beavers3, Gary Matusow4, Ruby Leong5, Nathalie Lambert6, Coen Bernaards7, Jonathan Solsky5, Barbara J Brennan5,... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.